Inhibitory deficits are characteristic of the mania of Bipolar Disorder (BD) and provide a behavioral target for translational research. The primary focus of this translational project is to assess deficits in three domains of inhibition in manic BD patients and in parallel animal models based on pharmacological challenges and gene engineering technology. Extensive animal data as well as recent findings linking BD to alterations in the genetic sequence in the vicinity of the dopamine transporter (DAT) gene support the basic hypothesis that the manic state involves a dysregulation of dopaminergic systems. This project uses and further develops cross-species measures that reflect abnormalities in dopaminergic systems to advance our understanding of BD and its treatment. The design involves parallel studies in manic BD patients and in mice in which the DAT has been manipulated either pharmacologically (amphetamine) or genetically (DAT knockdown and knockout mice). Specifically, inhibitory deficits in three domains will be assessed: 1. Impaired sensorimotor inhibition using prepulse inhibition of startle; 2. Motor hyperactivity in a novel environment using species-appropriate ambulatory monitoring devices; and, 3. Perseveration using innovative non-linear analyses of spatial and temporal patterns of motor responses. Manic BD inpatients will be studied at hospital admission, when highly symptomatic, and longitudinally during treatment with antimanic and/or atypical antipsychotic drugs. Normal comparison subjects will also be studied longitudinally, although in the absence of treatment. An important innovative aspect of this application is the development of an explicit human analog of the open field, the classic rodent behavioral paradigm used to assess dopaminergic psychostimulant effects. Experiments with mice will test the hypothesis that mutant mice lacking the normal complement of DAT might serve as a model of the inhibitory deficits in BD and that DAT-deficient mice might provide an animal model with predictive validity for the identification of antimanic agents. The parallel characterization of core features of BD across species will enable objective measures of mania that can be used to monitor treatment efficacy in BD patients and facilitate the validation of homologous predictive models of BD in rodents. Such preclinical models, and the human measures essential to their validation, are critical to the future discovery of novel treatments of this condition.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH071916-02
Application #
6942955
Study Section
Special Emphasis Panel (ZMH1-NRB-Q (05))
Program Officer
Meinecke, Douglas L
Project Start
2004-08-25
Project End
2009-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
2
Fiscal Year
2005
Total Cost
$385,000
Indirect Cost
Name
University of California San Diego
Department
Psychiatry
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
MacQueen, David A; Minassian, Arpi; Henry, Brook L et al. (2018) Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults. J Int Neuropsychol Soc 24:283-293
Milienne-Petiot, Morgane; Geyer, Mark A; Arnt, Jørn et al. (2017) Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl) 234:1017-1028
Milienne-Petiot, Morgane; Kesby, James P; Graves, Mary et al. (2017) The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania. Neuropharmacology 113:260-270
Cope, Zackary A; Young, Jared W (2017) The Five-Choice Continuous Performance Task (5C-CPT): A Cross-Species Relevant Paradigm for Assessment of Vigilance and Response Inhibition in Rodents. Curr Protoc Neurosci 78:9.56.1-9.56.18
Swerdlow, Neal R; Braff, David L; Geyer, Mark A (2016) Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol 30:1072-1081
Perry, William; McIlwain, Meghan; Kloezeman, Karen et al. (2016) Diagnosis and characterization of mania: Quantifying increased energy and activity in the human behavioral pattern monitor. Psychiatry Res 240:278-283
Minassian, Arpi; Young, Jared W; Cope, Zackary A et al. (2016) Amphetamine increases activity but not exploration in humans and mice. Psychopharmacology (Berl) 233:225-33
van Enkhuizen, Jordy; Milienne-Petiot, Morgane; Geyer, Mark A et al. (2015) Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology (Berl) 232:3455-67
Young, J W; Geyer, M A (2015) Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol 29:178-96
van Enkhuizen, Jordy; Geyer, Mark A; Minassian, Arpi et al. (2015) Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models: Rodent and human studies. Neurosci Biobehav Rev 58:4-18

Showing the most recent 10 out of 68 publications